Oscar Health, Inc. (NYSE:OSCR) Receives $20.78 Average Target Price from Analysts

Oscar Health, Inc. (NYSE:OSCR) has been assigned an average rating of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.7778.

A number of research firms have issued reports on OSCR. Barclays raised Oscar Health from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $30.00 to $35.00 in a report on Wednesday, June 10th. Weiss Ratings downgraded Oscar Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday. UBS Group raised their price objective on Oscar Health from $15.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Jefferies Financial Group upgraded Oscar Health from an “underperform” rating to a “hold” rating and raised their price objective for the stock from $10.00 to $16.00 in a research report on Monday, April 20th. Finally, Wells Fargo & Company set a $20.00 price objective on Oscar Health and gave the stock an “equal weight” rating in a research report on Thursday, June 4th.

Oscar Health Stock Performance

OSCR opened at $29.77 on Friday. The firm has a market capitalization of $8.97 billion, a P/E ratio of -50.45, a price-to-earnings-growth ratio of 2.08 and a beta of 2.37. The stock’s 50 day moving average price is $23.03 and its two-hundred day moving average price is $17.36. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.26. Oscar Health has a 12-month low of $10.69 and a 12-month high of $30.38.

Oscar Health (NYSE:OSCR) last released its earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. The firm had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The company’s revenue was up 52.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 EPS. On average, equities analysts forecast that Oscar Health will post 0.47 earnings per share for the current year.

Insider Buying and Selling at Oscar Health

In related news, insider Janet Liang sold 12,475 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $273,701.50. Following the completion of the transaction, the insider owned 259,057 shares in the company, valued at $5,683,710.58. This trade represents a 4.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mario Schlosser sold 880,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $29.38, for a total value of $25,854,400.00. Following the sale, the director directly owned 480,866 shares of the company’s stock, valued at $14,127,843.08. This represents a 64.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,217,160 shares of company stock worth $34,471,090 over the last three months. 24.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oscar Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC acquired a new stake in Oscar Health during the 1st quarter valued at $6,234,000. Bank of America Corp DE increased its holdings in Oscar Health by 205.1% during the 1st quarter. Bank of America Corp DE now owns 2,860,310 shares of the company’s stock valued at $32,808,000 after purchasing an additional 1,922,732 shares in the last quarter. Arkadios Wealth Advisors increased its holdings in Oscar Health by 9.4% during the 1st quarter. Arkadios Wealth Advisors now owns 14,275 shares of the company’s stock valued at $164,000 after purchasing an additional 1,228 shares in the last quarter. Amundi acquired a new stake in shares of Oscar Health in the 1st quarter valued at $362,000. Finally, California State Teachers Retirement System increased its stake in shares of Oscar Health by 23.3% in the 1st quarter. California State Teachers Retirement System now owns 235,443 shares of the company’s stock valued at $2,701,000 after buying an additional 44,443 shares during the period. 75.70% of the stock is owned by institutional investors and hedge funds.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.